

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073364 A1

(51) International Patent Classification:

A61K 31/4375 (2006.01) C07D 471/04 (2006.01)
C07D 307/81 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/075047

(22) International Filing Date:

25 September 2023 (25.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/409,862 26 September 2022 (26.09.2022) US
63/515,217 24 July 2023 (24.07.2023) US

(71) Applicants: **BEIGENE, LTD.** [GB/GB]; c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay, PO Box 1348, Grand Cayman, KY1-1108 (KY).
MAPKURE, LLC [US/US]; c/o Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware 19808

(US). **AMGEN, INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventor: **LUO, Lusong**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing, Beijing 102206 (CN).

(74) Agent: **BAUR, Amelia Feulner** et al.; MCNEILL BAUR PLLC, 125 CAMBRIDGE PARK DRIVE, SUITE 301, CAMBRIDGE, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMBINATIONS OF A B-RAF INHIBITOR, AND AN ANTI-EGFR ANTIBODY FOR THE TREATMENT OF CANCER





Fig. 3

(57) Abstract: Provided here is a combination comprising (i) Compound A having the name of 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(2,4,5-trifluorophenyl) urea, or the structure of formula (I); or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopologue, solvate, or prodrug thereof; and an anti-EGFR antibody, e.g., panitumumab; compositions comprising the same; and methods of using such combinations and compositions in the treatment of cancer, e.g., colorectal cancer, pancreatic cancer, and non-small cell lung cancer.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*